AOD-9604
Also known as: Advanced Obesity Drug 9604, Anti-Obesity Drug, Tyr-hGH177–191
AOD-9604 is Tyr-hGH177–191, an engineered growth-hormone tail fragment. Positive animal observations did not establish human obesity efficacy, and food-ingredient claims do not establish an approved injectable medicine.
Quick Facts
Identity and the fragment distinction
AOD-9604 means Advanced Obesity Drug 9604, the weight-management candidate developed by Metabolic Pharmaceuticals. Its 16 residues comprise hGH177–191 plus an N-terminal tyrosine; intact hGH has 191 residues. AOD-9604 and the unmodified Fragment 176–191 should not be treated as exact aliases.
The FDA assessment distinguishes free base and acetate and gives the free-base molecular weight as 1,815.09 g/mol. A fragment name does not make salts or finished formulations interchangeable. Food-ingredient or GRAS positioning is not drug approval, injectable-quality evidence or proof of safety.
Experimental fat-metabolism mechanisms
The development rationale was to isolate GH-tail metabolic activity without reproducing the full hormone’s growth/glucose effects. Animal and cell work found increased lipolysis and fat oxidation and reduced fat storage, without demonstrated GH-receptor activation or the associated growth/insulin-resistance effects.
In obese Zucker rats, 19 days of treatment reduced body-weight gain and increased adipose lipolytic activity without the insulin-sensitivity effect observed with whole GH. Reduced gain is not the same as losing that percentage of initial body weight. Mouse experiments linked chronic effects to beta-3 adrenergic receptor expression, not a simple claim of direct beta-3 agonism. The findings do not establish targeted human abdominal-fat loss, muscle gain or absence of risk.
Human obesity research and differing trial accounts
A 2013 obesity-development review describes a 24-week Phase 2b trial of 536 participants with no significant weight-loss advantage versus placebo and termination of the obesity program in 2007. The earlier favorable signal did not replicate in that larger account.
The existing FDA OPTIONS account separately describes 502 adults randomized to oral AOD-9604 or placebo with diet/exercise over 24 weeks, with a nonsignificant primary 12-week weight-loss comparison. An earlier 300-person, 12-week study had favorable abstract-level signals with limited methods. These are explicitly attributed accounts: the 536 and 502 counts, and the 24-week versus primary 12-week descriptions, are not merged into one unqualified figure. Both accounts leave human weight-loss efficacy unestablished.
Other clinical and preclinical research
A 2013 sponsor-associated safety report describes six oral or short-IV studies with generally encouraging tolerability and glucose/IGF-1 observations. Those designs do not establish subcutaneous efficacy or indefinite safety.
A 32-rabbit osteoarthritis model found favorable cartilage/lameness results with intra-articular AOD-9604 and hyaluronic acid; the combination outperformed either alone on reported measures. This was not a completed human Phase II cartilage trial.
Later LAT8881 programs include neuropathic pain, migraine and IV safety/radicular pain. Posted pain comparisons did not show significant benefit. Their actual populations, routes and endpoints do not establish routine subcutaneous fat-loss efficacy.
Exposure and safety boundaries
No standard 250–500 microgram subcutaneous schedule, fasting rule, injection-near-fat-deposits technique or 8–12-week cycle is established. FDA had no human information for the nominated subcutaneous/transdermal uses at evaluation. Oral/IV studies and later LAT8881 work remain tied to their actual routes; a finished preparation needs its own handling and stability support.
The 2013 safety paper included serious diarrhea judged possibly related after a high single oral dose and chest tightness judged possibly related during acute IV exposure. Other reported events, including cancers, were judged unrelated by investigators. Event occurrence does not automatically establish causation. FDA discusses immunogenicity and impurity concerns and says identified serious-event causality is unclear. Neither favorable preclinical results nor limited tolerability observations establish that every route is side-effect-free.
Sources: [7]
Approval, compounding and sports
AOD-9604 has no FDA approval and did not become a marketed obesity drug. Its 503A nomination was withdrawn. FDA lists it among nominated-but-withdrawn substances, not as a current Category 2 entry. Removal after withdrawal in April 2026 was not a safety finding; Category 1 or bulks-list inclusion would require a separate step, without an established timeline. The described position does not provide a licensed US compounding-prescription pathway.
WADA prohibits AOD-9604 at all times. A 2013 analysis found that it did not register on the hGH isoform immunoassay, which does not establish nondetectability by other methods. A 2015 Drug Testing and Analysis report described a stable metabolite that may extend detection.
Tesamorelin is a different stabilized GHRH analog that stimulates endogenous GH and has specific product approval for HIV-associated abdominal fat. Its randomized findings do not rescue AOD-9604’s negative obesity program or confer approval on the GH fragment.
References and further reading
This reference draws on Superpower’s Peptide Library and the research linked below. Peptide Dossier’s editorial team adapted and integrated the material on .
- 10.1159/000053183Experimental fat-metabolism mechanismsCited in: Experimental fat-metabolism mechanisms
- 10.1038/sj.ijo.0801740Experimental fat-metabolism mechanismsCited in: Experimental fat-metabolism mechanisms
- pubmed.ncbi.nlm.nih.govHuman obesity research and differing trial accountsCited in: Human obesity research and differing trial accounts
- pubmed.ncbi.nlm.nih.govIdentity and the fragment distinctionCited in: Identity and the fragment distinction
- dailymed.nlm.nih.govIdentity and the fragment distinctionCited in: Identity and the fragment distinction
- pubmed.ncbi.nlm.nih.govApproval, compounding and sportsCited in: Approval, compounding and sports
- fda.govExposure and safety boundariesCited in: Exposure and safety boundaries
- wada-ama.orgApproval, compounding and sportsCited in: Approval, compounding and sports
- fda.govApproval, compounding and sportsCited in: Approval, compounding and sports
- accessdata.fda.govApproval, compounding and sportsCited in: Approval, compounding and sports
- pubmed.ncbi.nlm.nih.govApproval, compounding and sportsCited in: Approval, compounding and sports
- www.fda.gov — additional readingIdentity and the fragment distinction · Human obesity research and differing trial accountsCited in: Identity and the fragment distinction, Human obesity research and differing trial accounts
- pubmed.ncbi.nlm.nih.gov — additional reading
- pubmed.ncbi.nlm.nih.gov — additional reading
- www.jofem.org — additional readingOther clinical and preclinical researchCited in: Other clinical and preclinical research
- pubmed.ncbi.nlm.nih.gov — additional readingOther clinical and preclinical researchCited in: Other clinical and preclinical research
- clinicaltrials.gov — additional readingOther clinical and preclinical researchCited in: Other clinical and preclinical research
- clinicaltrials.gov — additional readingOther clinical and preclinical researchCited in: Other clinical and preclinical research
- clinicaltrials.gov — additional readingOther clinical and preclinical researchCited in: Other clinical and preclinical research
Frequently Asked Questions About AOD-9604
Animal metabolic findings are favorable, but the larger 502-person oral obesity trial did not show a significant primary weight-loss advantage over placebo. That result does not establish routine fat-loss injections or a predictable amount of weight loss.
The oral and acute-IV studies provide useful tolerability observations, not a guarantee of safety for every formulation or route. Possibly related adverse events were reported, and FDA identifies important safety-information gaps. Food-use GRAS claims are separate from drug approval.
AOD-9604 is a modified fragment, not full-length growth hormone or a growth-hormone secretagogue. Several studies did not find significant IGF-1 changes; this does not prove absence of every hormonal or metabolic risk across routes.
A reliable human fat-loss timeline is not established by the reviewed studies. Reports of visible changes after a few weeks cannot substitute for a controlled result or predict an individual response.
No. The larger obesity development program did not show a significant advantage over placebo. Positive rodent findings did not establish clinical weight-loss benefit.
No. AOD-9604 is 16-residue Tyr-hGH177–191, while intact hGH has 191 residues. Their structures, receptor interactions and evidence differ. Failure to register on one hGH assay does not imply nondetectability.
No. Food-ingredient positioning or GRAS assertions do not constitute drug approval. A withdrawn nomination does not establish 503A compounding eligibility.
The described September 2026 position has no eligible 503A pathway or approved drug formulation. Online research-vendor products are outside regulated pharmaceutical oversight.
Yes. WADA prohibits it at all times, and metabolite/detection research has been published.
No. Nomination withdrawal was not a safety finding or automatic Category 1/bulks-list inclusion. A separate classification or rulemaking action would be required.
Tesamorelin acts through pituitary GHRH receptors and has product-specific HIV-lipodystrophy approval. AOD-9604 is a modified GH tail fragment with unsuccessful obesity efficacy research; their clinical and regulatory records differ.
No FDA-approved drug formulation is described. The stated September 2026 position also lacks an eligible routine 503A compounding pathway; a prescription alone does not create product approval or compounding eligibility.
Related Peptides
Continue exploring AOD-9604
- AOD-9604 Before and After: Results & Timeline [2026]Guide
- AOD-9604 Benefits: Fat Loss & Metabolism [2026 Guide]Guide
- AOD-9604 Dosage Guide: Protocols & Charts [2026]Guide
- AOD-9604 Side Effects: Safety & Risk Profile [2026]Guide
- AOD-9604 vs HGH: Fat Loss, Muscle Effects & Human Evidence [2026]Comparison
- AOD-9604 vs Semaglutide: Weight Loss Comparison [2026]Guide
- AOD-9604: Fat Loss Peptide Guide and Research Review [2026]Guide
Our library review is ongoing. Read how we evaluate evidence or report a correction.
Disclaimer: This article is for informational and educational purposes only. It is not intended as medical advice. The information presented is based on published research and should not be used as a substitute for professional medical guidance. Always consult a qualified healthcare provider before starting any peptide protocol. Some peptides discussed may not be approved for human use by the FDA or equivalent regulatory bodies.